avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + Anastrozole
Phase 3Recruiting 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Low Grade Serous Ovarian Cancer
Conditions
Low Grade Serous Ovarian Cancer
Trial Timeline
Mar 18, 2024 โ Feb 9, 2031
NCT ID
NCT06072781About avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + Anastrozole
avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + Anastrozole is a phase 3 stage product being developed by Verastem Oncology for Low Grade Serous Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06072781. Target conditions include Low Grade Serous Ovarian Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06072781 | Phase 3 | Recruiting |
Competing Products
20 competing products in Low Grade Serous Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-ฮฑ-NET | Perspective Therapeutics | Phase 1 | 25 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 52 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Letrozole | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib + Mosunetuzumab | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 52 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 52 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Cilengitide | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |